In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers report that patients treated with immune checkpoint inhibitors have a higher self-reported quality of life than patients treated with other types of therapy.
A new collaboration between two Western New York cancer research leaders will help oncologists learn whether Black and white cancer patients respond differently to a game-changing immunotherapy treatment, and seeks to improve the safety and effectiveness of these newer drugs in diverse populations.
A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy. This discovery, published today in the journal Nature Communications, is not only an important step forward in lung cancer treatment, but also has implications for other malignancies, according to lead author Fumito Ito, MD, PhD, FACS.
A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells.
New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously.
New NCCN Guidelines for Patients: Immunotherapy Side Effects – Immune Checkpoint Inhibitors from National Comprehensive Cancer Network and NCCN Foundation shares information for patients and caregivers on how to recognize and manage adverse events from immune checkpoint inhibitors.
A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center.